Which patient populations benefit most from long-acting injectable buprenorphine (Buvidal) regarding treatment retention and reduction in opioid use?

Long-acting injectable buprenorphine (Buvidal) is shown to be effective in improving treatment retention and reducing opioid use in adults with opioid use disorder, although specific subpopulations deriving the most benefit are not clearly identified.

Published in Zenodo (CERN European Organization for Nuclear Research). The abstract is shown as published and remains the work of its authors; read the full article at the source.